^
    Back
    Association details:
    Biomarker:NTRK1 fusion
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Sarcoma)
    New
    Title:

    New sarcoma drug approved for use in England

    Excerpt:
    We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    JTO Clin Res Rep
    Title:

    Primary Resistance to Larotrectinib in a Patient with Squamous Non-Small Cell Lung Cancer with Subclonal NTRK1 Fusion: Case Report

    Published date:
    03/17/2023
    Excerpt:
    We report a case of a 75-year-old male with minimal smoking history with NTRK fusion-positive metastatic squamous NSCLC with primary resistance to larotrectinib.
    DOI:
    https://doi.org/10.1016/j.jtocrr.2023.100501